- The trend backdrop is active with a 48-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
POLB
LSE
Week ended 07 Aug 2026
Weekly Investor Report
Poolbeg Pharma PLC · Healthcare · Biotechnology
Latest close
0.08 GBP
23.9%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 53.0% above the Trend Line and sits at 89.2% of its 52-week range. The latest completed week returned 23.9%, after a 18.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100.
Setup score
70
out of 100
Latest Close
0.08 GBP
7 Aug 2026
1W Return
23.9%
latest completed week
4W Return
18.6%
short-term follow-through
12W Return
74.7%
quarterly tape
Trend Breadth
92.3%
48 of 52 weeks active
Volume Ratio
1.8x
vs 13-week average
- Recent volatility is running well above the one-year baseline.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
23.9%
Latest completed week; four-week move 18.6%.
Indicator stack
96/54
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
21 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 53.0% above the Trend Line and sits at 89.2% of its 52-week range. The latest completed week returned 23.9%, after a 18.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9212-week average 0.73
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.92Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 18.6% over four weeks, 74.7% over 12 weeks, and 225.5% over one year. The current trend has remained active for 48 consecutive weeks.
Performance by holding period
Active trend streak48 weeks
Active weeks in one year48
Trend breadth92.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.45Latest activity-pressure read.
Pressure change-46.8%Four-week change in activity pressure.
Leadership64.02Latest relative-leadership reading.
RS change23.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 52%
Model confidence 41%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength34/100Blend of value, momentum, and quality. Underlying universe rank 67; rank 1 is best.
Value39/100Relative valuation strength. Underlying universe rank 62; rank 1 is best.
Quality40/100Profitability and accounting quality. Underlying universe rank 61; rank 1 is best.
Momentum40/100Medium-term price momentum. Underlying universe rank 61; rank 1 is best.
Growth40/100Revenue and earnings growth. Underlying universe rank 61; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- - Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 1/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- - Net share repurchases relative to market value.
- Shareholder yield
- - Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 21 relevant articles.
2 positive · 19 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-7.8%Distance below the 52-week high.
13-week volatility15.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2611 weeks finished lower.
Best week+47.0%Week of 5 Jun.
Worst week-12.1%Week of 17 Jul.
Latest week+23.9%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains6
Flat weeks2
Modest losses5
Sharp losses6
Recent vol15.5%13-week weekly-return volatility.
Base vol10.7%52-week weekly-return volatility.
Up/down split28/19Count of positive and negative weeks in the 52-week window.
Average skew9.4% / -6.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank5 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Biotechnology
4-week rank1 / 29
Group average-4.7%
Trend breadth13.8%
Trend13.8%active weekly trend signals
MD31.0%positive activity pressure
RS17.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape68/100
Trend, activity pressure, participation, and risk combine to a 68/100 tape read.
Indicator analysis88/100Latest 12-week confirmation: trend 12/12, activity pressure 11/12, relative leadership 12/12.
Activity pressure 0.92; No reversal markers Factors37/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 50 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 21 relevant articles.
REG - Poolbeg Pharma PLC - Notification of major holdings Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.08 GBP | 23.9% | 0.05 GBP | 0.07 GBP | 0.45 | 64.02 | 19.6M | On |
| 31 Jul 2026 | 0.07 GBP | 8.9% | 0.05 GBP | 0.07 GBP | 0.40 | 35.50 | 6.3M | On |
| 24 Jul 2026 | 0.06 GBP | 0.0% | 0.05 GBP | 0.07 GBP | 0.54 | 27.63 | 7.4M | On |
| 17 Jul 2026 | 0.06 GBP | -12.1% | 0.05 GBP | 0.07 GBP | 0.71 | 30.69 | 41.2M | On |
| 10 Jul 2026 | 0.07 GBP | 2.2% | 0.05 GBP | 0.07 GBP | 0.85 | 51.78 | 3.5M | On |
| 3 Jul 2026 | 0.07 GBP | 1.5% | 0.05 GBP | 0.07 GBP | 1.03 | 48.00 | 1.9M | On |
| 26 Jun 2026 | 0.07 GBP | -11.2% | 0.05 GBP | 0.07 GBP | 1.31 | 50.03 | 361.7K | On |
| 19 Jun 2026 | 0.08 GBP | -1.3% | 0.05 GBP | 0.07 GBP | 1.52 | 73.36 | 1.3M | On |
| 12 Jun 2026 | 0.08 GBP | -10.5% | 0.05 GBP | 0.07 GBP | 1.33 | 76.70 | 1.3M | On |
| 5 Jun 2026 | 0.09 GBP | 47.0% | 0.04 GBP | 0.07 GBP | 1.01 | 102.50 | 43.1M | On |
| 29 May 2026 | 0.06 GBP | 16.1% | 0.04 GBP | 0.07 GBP | 0.44 | 39.98 | 10.8M | On |
| 22 May 2026 | 0.05 GBP | 6.1% | 0.04 GBP | 0.07 GBP | -0.10 | 21.08 | 2.9M | On |
| 15 May 2026 | 0.05 GBP | 9.2% | 0.04 GBP | 0.07 GBP | -0.30 | 18.29 | 3.9M | On |
| 8 May 2026 | 0.04 GBP | 1.2% | 0.04 GBP | 0.07 GBP | -0.38 | 8.66 | 5.1M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.